Copyright Reports & Markets. All rights reserved.

Global Restless Legs Syndrome Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Restless Legs Syndrome by Type
    • 1.3.1 Overview: Global Restless Legs Syndrome Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Restless Legs Syndrome Consumption Value Market Share by Type in 2023
    • 1.3.3 Pharmacological Therapy
    • 1.3.4 Non-Pharmacological Therapy
  • 1.4 Global Restless Legs Syndrome Market by Application
    • 1.4.1 Overview: Global Restless Legs Syndrome Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Below 35 Years Old
    • 1.4.3 From 35 to 50 Years Old
    • 1.4.4 Above 50 Years Old
  • 1.5 Global Restless Legs Syndrome Market Size & Forecast
  • 1.6 Global Restless Legs Syndrome Market Size and Forecast by Region
    • 1.6.1 Global Restless Legs Syndrome Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Restless Legs Syndrome Market Size by Region, (2019-2030)
    • 1.6.3 North America Restless Legs Syndrome Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Restless Legs Syndrome Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Restless Legs Syndrome Market Size and Prospect (2019-2030)
    • 1.6.6 South America Restless Legs Syndrome Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East & Africa Restless Legs Syndrome Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Boehringer Ingelheim GmbH
    • 2.1.1 Boehringer Ingelheim GmbH Details
    • 2.1.2 Boehringer Ingelheim GmbH Major Business
    • 2.1.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Product and Solutions
    • 2.1.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
  • 2.2 UCB SA
    • 2.2.1 UCB SA Details
    • 2.2.2 UCB SA Major Business
    • 2.2.3 UCB SA Restless Legs Syndrome Product and Solutions
    • 2.2.4 UCB SA Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 UCB SA Recent Developments and Future Plans
  • 2.3 Astellas
    • 2.3.1 Astellas Details
    • 2.3.2 Astellas Major Business
    • 2.3.3 Astellas Restless Legs Syndrome Product and Solutions
    • 2.3.4 Astellas Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Astellas Recent Developments and Future Plans
  • 2.4 Arbor Pharmaceuticals
    • 2.4.1 Arbor Pharmaceuticals Details
    • 2.4.2 Arbor Pharmaceuticals Major Business
    • 2.4.3 Arbor Pharmaceuticals Restless Legs Syndrome Product and Solutions
    • 2.4.4 Arbor Pharmaceuticals Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Arbor Pharmaceuticals Recent Developments and Future Plans
  • 2.5 GlaxoSmithKline plc.
    • 2.5.1 GlaxoSmithKline plc. Details
    • 2.5.2 GlaxoSmithKline plc. Major Business
    • 2.5.3 GlaxoSmithKline plc. Restless Legs Syndrome Product and Solutions
    • 2.5.4 GlaxoSmithKline plc. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 GlaxoSmithKline plc. Recent Developments and Future Plans
  • 2.6 Ligand Pharmaceuticals Incorporated
    • 2.6.1 Ligand Pharmaceuticals Incorporated Details
    • 2.6.2 Ligand Pharmaceuticals Incorporated Major Business
    • 2.6.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product and Solutions
    • 2.6.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Ligand Pharmaceuticals Incorporated Recent Developments and Future Plans
  • 2.7 axxonis Pharma AG
    • 2.7.1 axxonis Pharma AG Details
    • 2.7.2 axxonis Pharma AG Major Business
    • 2.7.3 axxonis Pharma AG Restless Legs Syndrome Product and Solutions
    • 2.7.4 axxonis Pharma AG Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 axxonis Pharma AG Recent Developments and Future Plans
  • 2.8 Kyowa Hakko Kirin Co.
    • 2.8.1 Kyowa Hakko Kirin Co. Details
    • 2.8.2 Kyowa Hakko Kirin Co. Major Business
    • 2.8.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product and Solutions
    • 2.8.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Kyowa Hakko Kirin Co. Recent Developments and Future Plans
  • 2.9 Jazz Pharmaceuticals, Inc.
    • 2.9.1 Jazz Pharmaceuticals, Inc. Details
    • 2.9.2 Jazz Pharmaceuticals, Inc. Major Business
    • 2.9.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product and Solutions
    • 2.9.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Jazz Pharmaceuticals, Inc. Recent Developments and Future Plans
  • 2.10 Omeros Corporation
    • 2.10.1 Omeros Corporation Details
    • 2.10.2 Omeros Corporation Major Business
    • 2.10.3 Omeros Corporation Restless Legs Syndrome Product and Solutions
    • 2.10.4 Omeros Corporation Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Omeros Corporation Recent Developments and Future Plans
  • 2.11 Manhattan Pharmaceuticals
    • 2.11.1 Manhattan Pharmaceuticals Details
    • 2.11.2 Manhattan Pharmaceuticals Major Business
    • 2.11.3 Manhattan Pharmaceuticals Restless Legs Syndrome Product and Solutions
    • 2.11.4 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Manhattan Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Restless Legs Syndrome Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Restless Legs Syndrome by Company Revenue
    • 3.2.2 Top 3 Restless Legs Syndrome Players Market Share in 2023
    • 3.2.3 Top 6 Restless Legs Syndrome Players Market Share in 2023
  • 3.3 Restless Legs Syndrome Market: Overall Company Footprint Analysis
    • 3.3.1 Restless Legs Syndrome Market: Region Footprint
    • 3.3.2 Restless Legs Syndrome Market: Company Product Type Footprint
    • 3.3.3 Restless Legs Syndrome Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Restless Legs Syndrome Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Restless Legs Syndrome Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Restless Legs Syndrome Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Restless Legs Syndrome Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Restless Legs Syndrome Consumption Value by Type (2019-2030)
  • 6.2 North America Restless Legs Syndrome Market Size by Application (2019-2030)
  • 6.3 North America Restless Legs Syndrome Market Size by Country
    • 6.3.1 North America Restless Legs Syndrome Consumption Value by Country (2019-2030)
    • 6.3.2 United States Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Restless Legs Syndrome Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Restless Legs Syndrome Consumption Value by Type (2019-2030)
  • 7.2 Europe Restless Legs Syndrome Consumption Value by Application (2019-2030)
  • 7.3 Europe Restless Legs Syndrome Market Size by Country
    • 7.3.1 Europe Restless Legs Syndrome Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 7.3.3 France Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Restless Legs Syndrome Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Restless Legs Syndrome Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Restless Legs Syndrome Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Restless Legs Syndrome Market Size by Region
    • 8.3.1 Asia-Pacific Restless Legs Syndrome Consumption Value by Region (2019-2030)
    • 8.3.2 China Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 8.3.5 India Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Restless Legs Syndrome Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Restless Legs Syndrome Consumption Value by Type (2019-2030)
  • 9.2 South America Restless Legs Syndrome Consumption Value by Application (2019-2030)
  • 9.3 South America Restless Legs Syndrome Market Size by Country
    • 9.3.1 South America Restless Legs Syndrome Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Restless Legs Syndrome Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Restless Legs Syndrome Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Restless Legs Syndrome Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Restless Legs Syndrome Market Size by Country
    • 10.3.1 Middle East & Africa Restless Legs Syndrome Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Restless Legs Syndrome Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Restless Legs Syndrome Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Restless Legs Syndrome Market Drivers
  • 11.2 Restless Legs Syndrome Market Restraints
  • 11.3 Restless Legs Syndrome Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Restless Legs Syndrome Industry Chain
  • 12.2 Restless Legs Syndrome Upstream Analysis
  • 12.3 Restless Legs Syndrome Midstream Analysis
  • 12.4 Restless Legs Syndrome Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
    According to our (Global Info Research) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
    Global key players of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, etc.
    Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.
    This report is a detailed and comprehensive analysis for global Restless Legs Syndrome market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global Restless Legs Syndrome market size and forecasts, in consumption value ($ Million), 2019-2030
    Global Restless Legs Syndrome market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
    Global Restless Legs Syndrome market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
    Global Restless Legs Syndrome market shares of main players, in revenue ($ Million), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Restless Legs Syndrome
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Restless Legs Syndrome market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Restless Legs Syndrome market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segmentation
    Restless Legs Syndrome market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Pharmacological Therapy
    Non-Pharmacological Therapy
    Market segment by Application
    Below 35 Years Old
    From 35 to 50 Years Old
    Above 50 Years Old
    Market segment by players, this report covers
    Boehringer Ingelheim GmbH
    UCB SA
    Astellas
    Arbor Pharmaceuticals
    GlaxoSmithKline plc.
    Ligand Pharmaceuticals Incorporated
    axxonis Pharma AG
    Kyowa Hakko Kirin Co.
    Jazz Pharmaceuticals, Inc.
    Omeros Corporation
    Manhattan Pharmaceuticals
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Restless Legs Syndrome product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Restless Legs Syndrome, with revenue, gross margin, and global market share of Restless Legs Syndrome from 2019 to 2024.
    Chapter 3, the Restless Legs Syndrome competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Restless Legs Syndrome market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Restless Legs Syndrome.
    Chapter 13, to describe Restless Legs Syndrome research findings and conclusion.

    Buy now